Effect of Autologous Cord Blood Mononuclear Cells for Digestive System in Preterm Neonates (ACBMNC)
Neonatal Necrotizing Enterocolitis, Growth and Development, Preterm Infants
About this trial
This is an interventional prevention trial for Neonatal Necrotizing Enterocolitis focused on measuring Necrotizing enterocolitis, Preterm infants, Prevention, cord blood mononuclear cells
Eligibility Criteria
Inclusion Criteria: (1) born at the study hospital; (2) singleton birth; (3) 26<GA <32 weeks; (4) free of severe congenital anomalies or genetic syndromes;
Exclusion criteria: (1) mothers with clinical chorioamnionitis; (2) the mother was opsitive for hepatitis B (HBsAg and/or HBeAg), hepatitis C (anti-HCV), syphilis, HIV (anti-HIV-1 and -2), and IgM against cytomegalovirus, rubella, toxoplasma, and herpes simplex viruses; (3) consent was not obtained from the parents or guardians; and (4) after processing, UCB cells were not available.
Sites / Locations
- Jie YangRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Autologous cord blood mononuclear cells
Placebo
Autologous Umbilical Cord Blood Mononuclear Cells Therapy 24 hours after birth ,dose is 50 million cells/kg
0.9% sodium chloride infusion 24 hours after birth